Suncoast Equity Management Buys Shares of 102,997 TuHURA Biosciences (NASDAQ:HURA)

Suncoast Equity Management purchased a new position in TuHURA Biosciences (NASDAQ:HURA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 102,997 shares of the company’s stock, valued at approximately $421,000. Suncoast Equity Management owned 0.24% of TuHURA Biosciences as of its most recent filing with the Securities and Exchange Commission.

Separately, Apollon Wealth Management LLC purchased a new stake in TuHURA Biosciences during the fourth quarter worth $253,000. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Stock Performance

NASDAQ HURA opened at $3.30 on Friday. The business has a fifty day moving average price of $4.41. TuHURA Biosciences has a 12-month low of $2.84 and a 12-month high of $14.60.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on HURA shares. Rodman & Renshaw initiated coverage on TuHURA Biosciences in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target on the stock. RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th. Finally, Maxim Group began coverage on shares of TuHURA Biosciences in a report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 target price for the company.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.